×
About 1,985 results

ALLMedicine™ Paroxysmal Nocturnal Hemoglobinuria Center

Research & Reviews  943 results

Paroxysmal Nocturnal Hemoglobinuria Presenting with Hemorrhagic Esophageal Varices.
https://doi.org/10.1016/j.amjmed.2020.09.026
The American Journal of Medicine; Wilson NR, Abbas HA et. al.

Oct 30th, 2020 - Paroxysmal Nocturnal Hemoglobinuria Presenting with Hemorrhagic Esophageal Varices.|2020|Wilson NR,Abbas HA,Kala J,|

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
https://doi.org/10.3324/haematol.2020.261826
Haematologica Risitano AM, Kulasekararaj AG et. al.

Oct 30th, 2020 - Paroxysmal nocturnal hemoglobinuria (PNH) is characterised by complement-mediated intravascular hemolysis (IVH) due to absence of complement regulators CD55 and CD59 on affected erythrocytes. Danicopan is a first-in-class oral proximal, complement...

Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis.
https://doi.org/10.1007/s10620-020-06670-z
Digestive Diseases and Sciences; Rocco A, Compare D et. al.

Oct 22nd, 2020 - Hepatitis-associated aplastic anemia is a well-recognized clinical syndrome in which marrow failure follows the development of hepatitis. Although aplastic anemia is intimately related to paroxysmal nocturnal hemoglobinuria, until now, no cases of...

Utility of FLAER and CD157 in a five-color single-tube high sensitivity assay, for diag...
https://doi.org/10.1111/ijlh.13366
International Journal of Laboratory Hematology REFERENCES; Seth N, Mahajan V et. al.

Oct 15th, 2020 - FLAER-based flow cytometry assay is considered the gold standard for diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). CD157 is a recently reported marker for GPI-anchored protein found both on neutrophils and monocytes. This study highlight...

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targe...
https://doi.org/10.1007/s40262-020-00940-9
Clinical Pharmacokinetics; Badri P, Jiang X et. al.

Oct 13th, 2020 - Cemdisiran, an N-acetylgalactosamine (GalNAc) conjugated RNA interference (RNAi) therapeutic, is currently under development for the treatment of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein. This study...

see more →

Guidelines  2 results

Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and ...
https://doi.org/10.1002/cyto.b.20525
Cytometry. Part B, Clinical Cytometry; Borowitz MJ, Craig FE et. al.

Jun 9th, 2010 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell disorder characterized by a somatic mutation in the PIGA gene, leading to a deficiency of proteins linked to the cell membrane via glycophosphatidylinositol (GPI) anchors....

SOLIRIS® (ECULIZUMAB)
https://alexion.com/Products/Soliris

Soliris® is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion. Soliris® works by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  975 results

Paroxysmal Nocturnal Hemoglobinuria Presenting with Hemorrhagic Esophageal Varices.
https://doi.org/10.1016/j.amjmed.2020.09.026
The American Journal of Medicine; Wilson NR, Abbas HA et. al.

Oct 30th, 2020 - Paroxysmal Nocturnal Hemoglobinuria Presenting with Hemorrhagic Esophageal Varices.|2020|Wilson NR,Abbas HA,Kala J,|

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
https://doi.org/10.3324/haematol.2020.261826
Haematologica Risitano AM, Kulasekararaj AG et. al.

Oct 30th, 2020 - Paroxysmal nocturnal hemoglobinuria (PNH) is characterised by complement-mediated intravascular hemolysis (IVH) due to absence of complement regulators CD55 and CD59 on affected erythrocytes. Danicopan is a first-in-class oral proximal, complement...

Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis.
https://doi.org/10.1007/s10620-020-06670-z
Digestive Diseases and Sciences; Rocco A, Compare D et. al.

Oct 22nd, 2020 - Hepatitis-associated aplastic anemia is a well-recognized clinical syndrome in which marrow failure follows the development of hepatitis. Although aplastic anemia is intimately related to paroxysmal nocturnal hemoglobinuria, until now, no cases of...

Ultomiris - ravulizumab solution, concentrate-Alexion Pharmaceuticals Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a590d9-0217-43c7-908d-e62a71279791

Oct 18th, 2020 - ULTOMIRIS is indicated for: the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complem...

Utility of FLAER and CD157 in a five-color single-tube high sensitivity assay, for diag...
https://doi.org/10.1111/ijlh.13366
International Journal of Laboratory Hematology REFERENCES; Seth N, Mahajan V et. al.

Oct 15th, 2020 - FLAER-based flow cytometry assay is considered the gold standard for diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). CD157 is a recently reported marker for GPI-anchored protein found both on neutrophils and monocytes. This study highlight...

see more →

News  59 results

The evolving landscape of complement inhibition therapy
https://www.mdedge.com/fedprac/article/215831/anemia/evolving-landscape-complement-inhibition-therapy?channel=41022
I. Romina Sosa, MD, PhD

Jan 21st, 2020 - The introduction of eculizumab, a monoclonal antibody targeting C5 of the complement cascade, revolutionized the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare hematologic disorder characterized by complement-mediated intravascular.

FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome
https://www.medscape.com/viewarticle/920120

Oct 20th, 2019 - The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 month or older with atypical hemolytic uremic synd...

C3 inhibitor shows potential in PNH and AIHA
https://www.mdedge.com/hematology-oncology/article/199135/anemia/c3-inhibitor-shows-potential-pnh-and-aiha?channel=39313
Will Pass

Apr 18th, 2019 - GLASGOW – APL-2, a complement factor 3 (C3) inhibitor, may be a future treatment option for paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA), according to investigators from two separate studies. Will Pass/MDedge Ne.

FDA approves ravulizumab for PNH
https://www.mdedge.com/hematology-oncology/article/192205/anemia/fda-approves-ravulizumab-pnh
HT Staff

Dec 25th, 2018 - Photo from Business Wire Ravulizumab (Ultomiris) The U. S.

FDA approves ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria
https://www.mdedge.com/familymedicine/article/191740/anemia/fda-approves-ravulizumab-treatment-paroxysmal-nocturnal
Hematology News; Lucas Franki

Dec 21st, 2018 - The Food and Drug Administration has approved ravulizumab (Ultomiris) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Wikimedia Commons/FitzColinGerald/Creative Commons License “The approval of Ultomir.

see more →

Patient Education  1 results see all →